On May 23, the FDA approved abiraterone acetate (Yonsa, Sun Pharmaceutical Industries Ltd.) in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Read the Sun Pharma press release here.
Posted 5/24/2018
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
